Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.

Slides:

Advertisements

Similar presentations

Nasal challenge with allergen leads to maxillary sinus inflammation

Advertisements

Molecular spreading and predictive value of preclinical IgE response to Phleum pratense in children with hay fever Laura Hatzler, Valentina Panetta,

Intradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms Anna Slovick, MRCS, Abdel Douiri, PhD,

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.

Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope–based grass pollen allergy vaccine with allergen extract–based vaccines

Birch pollen–related food allergy: Clinical aspects and the role of allergen-specific IgE and IgG4 antibodies Marija Geroldinger-Simic, MD, Thomas Zelniker,

Cor a 1–reactive T cells and IgE are predominantly cross-reactive to Bet v 1 in patients with birch pollen–associated food allergy to hazelnut Claudia.

Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery Albertien A.C. Aukema,

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy Satya D. Narisety,

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial Stephen.

High-titer IgE antibody specific for pollen allergens in northern California is associated with both wheezing and total serum IgE Elizabeth A. Erwin,

Kyoung-Bok Min, MD, PhD, Jin-Young Min, PhD

Petasol butenoate complex (Ze 339) relieves allergic rhinitis–induced nasal obstruction more effectively than desloratadine Alina F. Dumitru, MD, Mohamed.

Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody Seung Y. Chu, PhD, Holly M. Horton, PhD,

Effect of IVL745, a VLA-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma Virginia Norris, MRCP, Lee Choong, BSc, Duyen Tran,

Tolerant beekeepers display venom-specific functional IgG4 antibodies in the absence of specific IgE Eva-Maria Varga, MD, Fahima Kausar, MSc, Werner.

Designing hypoallergenic derivatives for allergy treatment by means of in silico mutation and screening Theresa Thalhamer, PhD, Heidi Dobias, MSc, Tatjana.

Cor a 1–reactive T cells and IgE are predominantly cross-reactive to Bet v 1 in patients with birch pollen–associated food allergy to hazelnut Claudia.

Skin test diagnosis of grass pollen allergy with a recombinant hybrid molecule Carine Metz-Favre, MD, Birgit Linhart, PhD, Margarete Focke-Tejkl, PhD,

Oral immunotherapy induces IgG antibodies that act through FcγRIIb to suppress IgE- mediated hypersensitivity Oliver T. Burton, PhD, Stephanie L. Logsdon,

David A. Khan, MD Journal of Allergy and Clinical Immunology

Birch pollen immunotherapy results in long-term loss of Bet v 1–specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies

Β-Glucan exacerbates allergic asthma independent of fungal sensitization and promotes steroid-resistant TH2/TH17 responses Zhonghua Zhang, MD, Jocelyn.

Is 9 more than 2 also in allergic airway inflammation?

The effects of house dust mite sublingual immunotherapy tablet on immunologic biomarkers and nasal allergen challenge symptoms Natasha C. Gunawardana,

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial Stephen.

Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge Yee Ean Ong, MBBS, Andrew Menzies-Gow,

Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies Louisa K. James, PhD, Mohamed H. Shamji,

Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope–based grass pollen allergy vaccine with allergen extract–based vaccines

Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy Albrecht Bufe, PhD, MD, Peter Eberle, MD, Eivy.

Clara cell 16-kd protein downregulates TH2 differentiation of human naive neonatal T cells Sofi Johansson, MSc, Göran Wennergren, MD, PhD, Nils Åberg,

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Intradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms Anna Slovick, MRCS, Abdel Douiri, PhD,

Corticosteroid insensitivity of chemokine expression in airway smooth muscle of patients with severe asthma Po-Jui Chang, MD, Pankaj K. Bhavsar, PhD,

Mohamed H. Shamji, PhD, Janice A. Layhadi, MSc, Guy W

IgG4 inhibits peanut-induced basophil and mast cell activation in peanut-tolerant children sensitized to peanut major allergens Alexandra F. Santos,

Endogenous polyclonal anti–IL-1 antibody responses potentiate IL-1 activity during pathogenic inflammation Gunther Spohn, PhD, Natalia Arenas-Ramirez,

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy Satya D. Narisety,

Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti–IL-4: A randomized controlled trial Adam M. Chaker, MD, Mohamed H. Shamji,

Debra J. Palmer, PhD, Thomas R. Sullivan, BMa&CompSc(Hons), Michael S

Airway epithelial cells activate TH2 cytokine production in mast cells through IL-1 and thymic stromal lymphopoietin Deepti R. Nagarkar, PhD, Julie A.

Grass tablet sublingual immunotherapy downregulates the TH2 cytokine response followed by regulatory T-cell generation Abel Suárez-Fueyo, PhD, Tania.

John A. Eckman, MD, Patricia M

What is an “eosinophilic phenotype” of asthma?

Allergen specificity of IgG4-expressing B cells in patients with grass pollen allergy undergoing immunotherapy Louisa K. James, PhD, Holly Bowen, PhD,

Jason B. Price, MD, Adnan Divjan, William R. Montfort, PhD, Kirstie H

Cockroach allergens: Coping with challenging complexity

Autophagy: Nobel Prize 2016 and allergy and asthma research

Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis Thomas B. Casale, MD, William.

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Mohamed H. Shamji, PhD, FAAAI, Stephen R. Durham, MD, FRCP

Sara Paveglio, PhD, MS, Erin Bennett, MS, Kelly L. Hawley, PhD, Adam P

Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years Ronald Dahl, MD,

Birch pollen–related food allergy: Clinical aspects and the role of allergen-specific IgE and IgG4 antibodies Marija Geroldinger-Simic, MD, Thomas Zelniker,

Long-term clinical efficacy in grass pollen–induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet Stephen.

Mechanisms of allergen-specific desensitization

Benjamin Chaigne, MD, Hervé Watier, MD, PhD

Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract Anil Nanda, MD, Maeve O'Connor, MD,

Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity James N. Francis, PhD, Louisa.

Nasal challenge with allergen leads to maxillary sinus inflammation

Profilin (Che a 2) and polcalcin (Che a 3) are relevant allergens of Chenopodium album pollen: Isolation, amino acid sequences, and immunologic properties

Early improvement in basophil sensitivity predicts symptom relief with grass pollen immunotherapy Johannes Martin Schmid, MD, Peter Adler Würtzen, PhD,

Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding Sven.

Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen Piyush Patel, MD, Tom Holdich, MBBS,

Allergen specificity of IgG4-expressing B cells in patients with grass pollen allergy undergoing immunotherapy Louisa K. James, PhD, Holly Bowen, PhD,

Safety and efficacy of repeated monthly carboplatin desensitization

The effects of gastric digestion on codfish allergenicity

Natural history of cow’s milk allergy

The influence of asthma control on the severity of virus-induced asthma exacerbations David J. Jackson, MRCP, PhD, Maria-Belen Trujillo-Torralbo, BSc,

Primary prevention of asthma and allergy

Presentation transcript:

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen R. Durham, MD, FRCP, Stephen J. Till, MRCP, PhD Journal of Allergy and Clinical Immunology Volume 130, Issue 4, Pages 918-924.e1 (October 2012) DOI: 10.1016/j.jaci.2012.06.052 Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Outline of study design. At each visit, indicated intradermal injections with 0.1, 1, and 10 BU of grass (P pratense) pollen extract were performed. The early and late responses were measured after 20 minutes and 24 hours, respectively. Journal of Allergy and Clinical Immunology 2012 130, 918-924.e1DOI: (10.1016/j.jaci.2012.06.052) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Cutaneous late responses (24 hours) to intradermal injection of 10 BU of grass (P pratense) and birch (B verrucosa) pollen extract at the final visit (visit 6). Bars indicate mean values. Comparisons among the 3 groups at visit 6 were performed by using 1-way ANOVA with posttest individual comparisons performed with the Bonferroni multiple comparison test. **P < .01 and ***P < .001. Journal of Allergy and Clinical Immunology 2012 130, 918-924.e1DOI: (10.1016/j.jaci.2012.06.052) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 Cutaneous early responses (20 minutes) to intradermal injection of 10 BU of grass (P pratense) and birch (B verrucosa) pollen extract at the final visit (visit 6). Bars indicate mean values. Comparisons among the 3 groups at visit 6 were performed by using 1-way ANOVA. Journal of Allergy and Clinical Immunology 2012 130, 918-924.e1DOI: (10.1016/j.jaci.2012.06.052) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 4 Time course of suppression of allergen-induced late responses in group A subjects. Data shown represent the mean ± SEM area of late responses measured 24 hours after intradermal injection of 0.1, 1.0, or 10 BU of P pratense grass pollen extract at 6 repeat visits separated by 2-week intervals. For each allergen dose, significance was assessed by using repeated measures ANOVA, followed by posttest comparison with visit 1 (baseline) using the Bonferroni multiple comparison test. Journal of Allergy and Clinical Immunology 2012 130, 918-924.e1DOI: (10.1016/j.jaci.2012.06.052) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 5 Effect of repeated intradermal injection with P pratense grass pollen extract on allergen-specific IgE and IgG titers together with inhibitory activity against IgE–grass pollen complex binding in the FAB assays. Sera were collected before intradermal injection at the visit shown and analyzed by using ELISA. For group A, significance was assessed by using repeated measures ANOVA, followed by posttest comparisons of different time points using the Bonferroni multiple comparison test. **P < .01. For group B, baseline and week 10 measurements were compared with the paired Student t test. Journal of Allergy and Clinical Immunology 2012 130, 918-924.e1DOI: (10.1016/j.jaci.2012.06.052) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E1 Comparison of inhibition of early versus late responses after repeated intradermal grass pollen injections in group A. Data shown represent the mean ± SEM percentage inhibition of early- and late-response area at visit 6 compared with visit 1. Significance was assessed with the paired Student t test. ***P < .001. EPR, Early-phase response; LPR, late-phase response. Journal of Allergy and Clinical Immunology 2012 130, 918-924.e1DOI: (10.1016/j.jaci.2012.06.052) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions